AI Analyst Summary
Aveanna Healthcare is a compelling value-growth combination in the Medical Care Facilities space, trading at just 9.8x trailing earnings despite delivering 38.5% YoY EPS growth and 13.7% revenue expansion — implying a highly attractive sub-1.0 PEG on an implied basis. The company has beaten earnings estimates in each of the last 4 quarters, signaling strong operational execution and margin discipline in a home health and hospice model that benefits from secular tailwinds in lower-cost care delivery. The key risk is that the analyst consensus price target of $12.35 sits marginally below the current price of $12.69, suggesting limited near-term upside as priced by the Street even with robust fundamentals.
Fundamentals
Pe
Trailing P/E: 9.8x | Forward P/E: 14.7x · 5.0/5
Trailing P/E of 9.8x is materially below the Healthcare/Medical Care Facilities sector median, offering compelling value relative to peers. The forward P/E expansion to 14.7x reflects expected earnings normalization but remains reasonable given growth trajectory.
Peg
N/A · 4.0/5
PEG ratio is not available. However, with 38.5% YoY earnings growth against a trailing P/E of just 9.8x, the implied PEG is well below 1.0, suggesting the stock is significantly undervalued relative to its growth rate. Scored above neutral based on this strong implied signal.
Analyst Rating
Buy consensus (1.7) · 4.0/5
Consensus rating of 1.7 from 10 analysts (8 Buy, 3 Hold, 0 Sell) reflects broad bullish sentiment with no sell-side opposition. Rating falls in the 1.5–2.5 range, mapping to a score of 4. Analyst conviction is high given the clean distribution.
Earnings Trend
EPS Growth +38.5% YoY | Revenue Growth +13.7% YoY · 5.0/5
Earnings growth of 38.5% YoY is well above the 25% threshold for a top score, supported by solid revenue growth of 13.7%. The combination of strong top-line expansion and accelerating earnings leverage indicates improving operational efficiency and a compelling growth trend.
Price Target Beat
4 of 4 quarters beat (last 4 quarters) · 3.0/5
EPS beat rate of 4 of 4 recent quarters is a positive signal for execution quality, but only 4 quarters of data are available. Per scoring guidelines, a full 8-quarter history is required to score above 3; with limited history, a neutral score of 3 is applied conservatively, though the perfect recent beat record is encouraging.
Management
Consistent executor with strong analyst confidence · 4.0/5
A perfect 4-for-4 EPS beat record and zero sell ratings from a 10-analyst panel signal strong management credibility and execution. Capital allocation appears disciplined given earnings outpacing revenue growth, indicating margin management. Scored 4 rather than 5 due to limited multi-year beat history.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.